(Total Views: 705)
Posted On: 10/23/2020 4:46:58 PM
Post# of 154318
I hear what the unblind now crowd is saying and there are legit points made. But I don’t think the Remdesivir approval will have much of an impact on enrollment.
Patient goes to hospital for COVID. Patient gets prescribed Remdesivir.
WHO study reveals Remdesivir is not very effective.
Remdesivir does not work, patient deteriorates to or maintains Severe/Critical illness. (Depends on timing of Remdesivir dosing: M/M or already Severe).
Patient given option to join Leronlimab trial with zero change to SOC.
Patient is very ill and has nothing to lose, so they enroll.
Patient gets better
Patient goes to hospital for COVID. Patient gets prescribed Remdesivir.
WHO study reveals Remdesivir is not very effective.
Remdesivir does not work, patient deteriorates to or maintains Severe/Critical illness. (Depends on timing of Remdesivir dosing: M/M or already Severe).
Patient given option to join Leronlimab trial with zero change to SOC.
Patient is very ill and has nothing to lose, so they enroll.
Patient gets better
(10)
(0)
